<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Adenovirus" exact="infections" post="of immunocompromised patients can cause a severe multi-organ disease"/>
 <result pre="Adenovirus infections of immunocompromised patients can cause a severe multi-organ" exact="disease" post="that often results in the patientsâ€™ death. Presently, there"/>
 <result pre="cases of adenovirus infections. To facilitate the development of effective," exact="non-toxic" post="antivirals against adenovirus, we have developed a permissive animal"/>
 <result pre="tissue macrophages to a lesser extent. HAdV-C6 has a 10-fold" exact="lower" post="LD50 in hamsters than HAdV-C5 and the pathology is"/>
 <result pre="drug that was shown to be active against intravenous HAdV-C5" exact="infection" post="previously, is efficacious against HAdV-C6 when administered either prophylactically"/>
 <result pre="to a lesser extent CDV, can be used to treat" exact="respiratory" post="adenovirus infections in the hamster model. These results extend"/>
 <result pre="lesser extent CDV, can be used to treat respiratory adenovirus" exact="infections" post="in the hamster model. These results extend the utility"/>
 <result pre="that consist of over 70 types (e.g., human species C" exact="type 5" post="adenovirus [HAdV-C5; referred to as Ad5 in this paper])"/>
 <result pre="biology, see [1,2]). Ads are widespread and generally cause mild" exact="infections" post="in immunocompetent adults that resolve without serious consequences (for"/>
 <result pre="Ad epidemiology and pathology, see [3]). The symptoms of Ad" exact="infection" post="depend on the type that caused the infection; e.g.,"/>
 <result pre="types belonging to species B, C, and E usually cause" exact="respiratory" post="disease, species F Ads cause enteric infection, and some"/>
 <result pre="and some of the species D viruses are implicated in" exact="ocular" post="illnesses. Infection with Ads usually happens in early childhood"/>
 <result pre="of the species D viruses are implicated in ocular illnesses." exact="Infection" post="with Ads usually happens in early childhood (ca. 60%"/>
 <result pre="in ocular illnesses. Infection with Ads usually happens in early" exact="childhood" post="(ca. 60% of patients with Ad infection are 5"/>
 <result pre="happens in early childhood (ca. 60% of patients with Ad" exact="infection" post="are 5 years old or younger [4]). After recovering"/>
 <result pre="long-term immunity to that specific type. In some instances, Ad" exact="infection" post="of healthy adults can cause serious illness; certain species"/>
 <result pre="Ads cause epidemic keratoconjunctivitis, which can result even in blindness." exact="Infection" post="with some species B Ads is endemic among military"/>
 <result pre="species B Ads is endemic among military recruits, causing severe" exact="acute" post="respiratory disease (for Ad pathology, see [3,5,6]). However, it"/>
 <result pre="B Ads is endemic among military recruits, causing severe acute" exact="respiratory" post="disease (for Ad pathology, see [3,5,6]). However, it is"/>
 <result pre="Ads is endemic among military recruits, causing severe acute respiratory" exact="disease" post="(for Ad pathology, see [3,5,6]). However, it is immunocompromised"/>
 <result pre="of these patients cannot eliminate the virus, and thus the" exact="infection" post="can lead to a serious, often life-threatening multi-organ illness."/>
 <result pre="infection can lead to a serious, often life-threatening multi-organ illness." exact="Pediatric" post="allogeneic hematopoietic stem cell transplant (HSCT) patients are especially"/>
 <result pre="transplant (HSCT) patients are especially threatened. The incidence of Ad" exact="infection" post="is between 3% and 47% for these patients, and"/>
 <result pre="however, CDV is kidney toxic, and thus its use is" exact="limited" post="to the most serious cases [14]. Ribavirin and to"/>
 <result pre="also been used (for reviews, see [3,5,6,7,8,9,10,11,15,16]). Brincidofovir (BCV, hexadecyloxypropyl-cidofovir," exact="formerly" post="known as CMX001), a less toxic derivative of CDV,"/>
 <result pre="the efficacy of anti-adenoviral compounds [24,25,26,27]. To mimic disseminated Ad" exact="infection" post="in immunocompromised patients, the animals are immunosuppressed by cyclophosphamide"/>
 <result pre="Ad infections. We have demonstrated that the symptoms of Ad5" exact="infection" post="in hamsters can be mitigated or even reversed with"/>
 <result pre="time, we also show that a drug is effective against" exact="respiratory" post="challenge with Ad. 2. Materials and Methods 2.1. Cells"/>
 <result pre="2. Materials and Methods 2.1. Cells and Viruses A549 human" exact="lung adenocarcinoma" post="cells were purchased from the American Type Culture Collection"/>
 <result pre="Materials and Methods 2.1. Cells and Viruses A549 human lung" exact="adenocarcinoma" post="cells were purchased from the American Type Culture Collection"/>
 <result pre="Viruses A549 human lung adenocarcinoma cells were purchased from the" exact="American" post="Type Culture Collection (ATCC) (Manassas, VA, USA), while HEK293"/>
 <result pre="CDV was obtained from the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID) and dissolved in phosphate-buffered saline (PBS) at"/>
 <result pre="was obtained from the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID) and dissolved in phosphate-buffered saline (PBS) at 3.7"/>
 <result pre="Envigo (Indianapolis, IN, USA) at approximately 100 g body weight." exact="Female" post="animals were used for all experiments except the repeat"/>
 <result pre="and were conducted according to federal and institutional regulations. 2.4." exact="Infection" post="of Hamsters with Adenovirus The animals were immunosuppressed using"/>
 <result pre="the collected organs and was quantified by 50% Tissue Culture" exact="Infectious" post="Dose (TCID50) assay in HEK-293 cells [24]. A portion"/>
 <result pre="noted for the Ad-infected VGCV-treated animals; for these hamsters, minimal" exact="acute" post="inflammation was the only significant histopathological finding. To quantify"/>
 <result pre="and kidney samples were collected at necropsy and analyzed for" exact="infectious" post="virus burden. Vehicle-treated Ad-infected animals had a very high"/>
 <result pre="levels (Figure 2). 3.2. Therapeutic Treatment with VGCV Prevents Ad6" exact="Infection-Induced" post="Mortality and Morbidity in Immunosuppressed Syrian Hamsters We demonstrated"/>
 <result pre="animals showed liver pathology that is characteristic of disseminated Ad" exact="infection" post="in this model. VGCV treatment completely prevented mortality in"/>
 <result pre="Virus Replication in the Lungs and Mitigates Morbidity after Ad6" exact="Respiratory" post="Infection of Immunosuppressed Female and Male Hamsters Respiratory infection"/>
 <result pre="Replication in the Lungs and Mitigates Morbidity after Ad6 Respiratory" exact="Infection" post="of Immunosuppressed Female and Male Hamsters Respiratory infection is"/>
 <result pre="Lungs and Mitigates Morbidity after Ad6 Respiratory Infection of Immunosuppressed" exact="Female" post="and Male Hamsters Respiratory infection is one of the"/>
 <result pre="after Ad6 Respiratory Infection of Immunosuppressed Female and Male Hamsters" exact="Respiratory" post="infection is one of the main routes by which"/>
 <result pre="Ad6 Respiratory Infection of Immunosuppressed Female and Male Hamsters Respiratory" exact="infection" post="is one of the main routes by which patients"/>
 <result pre="whether prophylactic administration of VGCV can affect the outcome of" exact="respiratory" post="Ad6 infection, we tested the efficacy of VGCV against"/>
 <result pre="which inhaled the liquid, thus delivering the virus to the" exact="lower" post="airways [29]. For the VGCV-treated animals, we used the"/>
 <result pre="collected at the Day 3 necropsy and were analyzed for" exact="infectious" post="virus burden. Vehicle-treated Ad6-infected animals had a very high"/>
 <result pre="of the experiment was identical to the one performed with" exact="female" post="animals, with the exception that the experiment was terminated"/>
 <result pre="7 days instead of 10 days post challenge. Similarly to" exact="female" post="hamsters, there were no treatment-related deaths in the study."/>
 <result pre="were collected at the Day 3 necropsy and analyzed for" exact="infectious" post="virus burden. We found that at 3 and 7"/>
 <result pre="5B). 3.4. CDV Mitigates Morbidity of Immunosuppressed Hamsters after Ad6" exact="Respiratory" post="Infection CDV is another compound that is known to"/>
 <result pre="3.4. CDV Mitigates Morbidity of Immunosuppressed Hamsters after Ad6 Respiratory" exact="Infection" post="CDV is another compound that is known to be"/>
 <result pre="with Ad5 [27]. To assess whether CDV is effective against" exact="respiratory" post="challenge with Ad6, we treated i.n.-infected hamsters with the"/>
 <result pre="to Ad5 [34]. The LD50 of Ad6 is ca. 10-fold" exact="lower" post="than that of Ad5, i.e., a 10-fold lower challenge"/>
 <result pre="ca. 10-fold lower than that of Ad5, i.e., a 10-fold" exact="lower" post="challenge dose is required to elicit the same pathology"/>
 <result pre="is also different; Ad5-infected hamsters lost more weight right after" exact="infection" post="than Ad6-infected ones; however, morbidity and mortality was greater"/>
 <result pre="the virus, for Ad6 (which can be given at a" exact="lower" post="dose), most of the pathogenicity is a result of"/>
 <result pre="have shown that several drugs were active against i.v. Ad5" exact="infection" post="[24,25,26,27,35]. However, none of these drugs was effective against"/>
 <result pre="infection [24,25,26,27,35]. However, none of these drugs was effective against" exact="respiratory" post="infection with the virus. The presumed reason for this"/>
 <result pre="[24,25,26,27,35]. However, none of these drugs was effective against respiratory" exact="infection" post="with the virus. The presumed reason for this inefficacy"/>
 <result pre="even in CP-treated animals, much of the pathology after intranasal" exact="infection" post="with Ad5 is the result of the immune response"/>
 <result pre="Ad5-based vector was nearly as pathogenic as Ad5. With the" exact="lower" post="LD50 of Ad6, we could decrease the input bolus"/>
 <result pre="the anti-adenoviral efficacy of VGCV; we received similar results with" exact="female" post="and male animals when treating them after i.n. challenge"/>
 <result pre="both Ad5 and Ad6 replicate in Syrian hamsters, a 10-fold" exact="lower" post="challenge dose of Ad6 than for Ad5 is required"/>
 <result pre="previous finding that VGCV is very effective against disseminated Ad" exact="infection" post="in the Syrian hamster model. Adding to this, we"/>
 <result pre="Adding to this, we demonstrated that VGCV is efficacious against" exact="respiratory" post="Ad infection of hamsters. In these studies, we chose"/>
 <result pre="this, we demonstrated that VGCV is efficacious against respiratory Ad" exact="infection" post="of hamsters. In these studies, we chose to use"/>
 <result pre="have reported previously that GCV was equally efficacious against HAdV-C5" exact="infection" post="in the hamster model [26]; thus, we believe that"/>
 <result pre="with federal funds from the National Institute of Allergy and" exact="Infectious" post="Diseases, National Institutes of Health, Department of Health and"/>
 <result pre="Williams &amp;amp; WilkinsPhiladelphia, PA, USA20131732 4.CollinsR.H.Jr.GoldsteinS.GiraltS.LevineJ.PorterD.DrobyskiW.BarrettJ.JohnsonM.KirkA.HorowitzM.et al.Donor leukocyte infusions in" exact="acute" post="lymphocytic leukemiaBone Marrow Transplant.20002651151611019840 5.IsonM.G.HaydenR.T.AdenovirusMicrobiol. Spectr.2016410.1128/microbiolspec.DMIH2-0020-2015 6.LynchJ.P.KajonA.E.Adenovirus: Epidemiology, global"/>
 <result pre="advances in treatment and preventionSemin. Respir. Crit. Care Med.20163758660210.1055/s-0031-128328727486739 7.IsonM.G.Adenovirus" exact="infections" post="in transplant recipientsClin. Infect. Dis.20064333133910.1086/50549816804849 8.EchavarriaM.Adenoviruses in immunocompromised hostsClin."/>
 <result pre="of adenovirus infectionsRev. Med. Virol.20081835737410.1002/rmv.58918655013 11.Matthes-MartinS.BoztugH.LionT.Diagnosis and treatment of adenovirus" exact="infection" post="in immunocompromised patientsExpert Rev. Anti-Infect. Ther.2013111017102810.1586/14787210.2013.83696424073835 12.SterczB.NagyK.OngradiJ.Adenovirus infections in"/>
 <result pre="of adenovirus infection in immunocompromised patientsExpert Rev. Anti-Infect. Ther.2013111017102810.1586/14787210.2013.83696424073835 12.SterczB.NagyK.OngradiJ.Adenovirus" exact="infections" post="in immunocompromised patientsOrv. Hetil.20121531896190410.1556/OH.2012.2949623183005 13.LionT.Adenovirus infections in immunocompetent and"/>
 <result pre="Rev. Anti-Infect. Ther.2013111017102810.1586/14787210.2013.83696424073835 12.SterczB.NagyK.OngradiJ.Adenovirus infections in immunocompromised patientsOrv. Hetil.20121531896190410.1556/OH.2012.2949623183005 13.LionT.Adenovirus" exact="infections" post="in immunocompetent and immunocompromised patientsClin. Microbiol. Rev.20142744146210.1128/CMR.00116-1324982316 14.IzzedineH.Launay-VacherV.DerayG.Antiviral drug-induced"/>
 <result pre="immunocompetent and immunocompromised patientsClin. Microbiol. Rev.20142744146210.1128/CMR.00116-1324982316 14.IzzedineH.Launay-VacherV.DerayG.Antiviral drug-induced nephrotoxicityAm. J." exact="Kidney" post="Dis.20054580481710.1053/j.ajkd.2005.02.01015861345 15.LenaertsL.NaesensL.Antiviral therapy for adenovirus infectionsAntivir. Res.20067117218010.1016/j.antiviral.2006.04.00716698093 16.WoldW.S.TothK.New drug"/>
 <result pre="and efficacy of cmx001 as salvage therapy for severe adenovirus" exact="infections" post="in immunocompromised patientsBiol. Blood Marrow Transplant.20121873173810.1016/j.bbmt.2011.09.00721963623 18.GrimleyM.PapanicolaouG.MaronG.ChittickG.BrundageT.BaeA.Mommej-MarinH.NicholsW.PrasadV.In Improved outcomes"/>
 <result pre="as salvage therapy for severe adenovirus infections in immunocompromised patientsBiol." exact="Blood" post="Marrow Transplant.20121873173810.1016/j.bbmt.2011.09.00721963623 18.GrimleyM.PapanicolaouG.MaronG.ChittickG.BrundageT.BaeA.Mommej-MarinH.NicholsW.PrasadV.In Improved outcomes in allogeneic hematopoietic cell"/>
 <result pre="(allo hct) patients treated with brincidofovir for disseminated adenovirus (AdV)" exact="disease" post="compared to literature: Updated preliminary results from the advise"/>
 <result pre="of the 41st Annual Meeting of the European Society for" exact="Blood" post="and Marrow TransplantationIstanbul, Turkey22â€“25 March 2015 19.GrimleyM.MaronG.PrasadV.JacobsohnD.YoungJ.ChittickG.BrundageT.Mommeja-MarinH.In Preliminary results"/>
 <result pre="February 2015 20.GrimleyM.S.ChemalyR.F.EnglundJ.A.KurtzbergJ.ChittickG.BrundageT.M.BaeA.MorrisonM.E.PrasadV.K.Brincidofovir for asymptomatic adenovirus viremia in pediatric and" exact="adult" post="allogeneic hematopoietic cell transplant recipients: A randomized placebo-controlled phase"/>
 <result pre="hematopoietic cell transplant recipients: A randomized placebo-controlled phase ii trialBiol." exact="Blood" post="Marrow Transplant.20172351252110.1016/j.bbmt.2016.12.62128063938 21.CamargoJ.F.MorrisM.I.AbboL.M.SimkinsJ.SaneeymehriS.AlencarM.C.LekakisL.J.KomanduriK.V.The use of brincidofovir for the treatment"/>
 <result pre="21.CamargoJ.F.MorrisM.I.AbboL.M.SimkinsJ.SaneeymehriS.AlencarM.C.LekakisL.J.KomanduriK.V.The use of brincidofovir for the treatment of mixed dsDNA" exact="viral" post="infectionJ. Clin. Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance of acyclovir-resistant herpes simplex"/>
 <result pre="mixed dsDNA viral infectionJ. Clin. Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance of acyclovir-resistant" exact="herpes" post="simplex virus-1 and adenovirus infection after stem cell transplantationTranspl."/>
 <result pre="Virol.2016831410.1016/j.jcv.2016.07.02127513204 22.VoigtS.HofmannJ.EdelmannA.SauerbreiA.KuhlJ.S.Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus" exact="infection" post="after stem cell transplantationTranspl. Infect. Dis.20161879179410.1111/tid.1258227482652 23.WoldW.S.TothK.Syrian hamster as"/>
 <result pre="oncolytic adenoviruses and to evaluate the efficacy of antiviral compoundsAdv." exact="Cancer" post="Res.2012115699223021242 24.TothK.SpencerJ.F.DharD.SagartzJ.E.BullerR.M.PainterG.R.WoldW.S.M.Hexadecyloxypropyl-cidofovir, cmx001, prevents adenovirus-induced mortality in a permissive,"/>
 <result pre="25.TothK.YingB.TollefsonA.E.SpencerJ.F.BalakrishnanL.SagartzJ.E.BullerR.M.WoldW.S.Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed" exact="female" post="and male syrian hamstersViruses201571409142810.3390/v703140925807051 26.YingB.TollefsonA.E.SpencerJ.F.BalakrishnanL.DewhurstS.CapellaC.BullerR.M.TothK.WoldW.S.Ganciclovir inhibits human adenovirus replication"/>
 <result pre="Agents Chemother.2014587171718110.1128/AAC.03860-1425224011 27.TollefsonA.E.SpencerJ.F.YingB.BullerR.M.WoldW.S.TothK.Cidofovir and brincidofovir reduce the pathology caused by" exact="systemic" post="infection with human type 5 adenovirus in immunosuppressed syrian"/>
 <result pre="Chemother.2014587171718110.1128/AAC.03860-1425224011 27.TollefsonA.E.SpencerJ.F.YingB.BullerR.M.WoldW.S.TothK.Cidofovir and brincidofovir reduce the pathology caused by systemic" exact="infection" post="with human type 5 adenovirus in immunosuppressed syrian hamsters,"/>
 <result pre="brincidofovir reduce the pathology caused by systemic infection with human" exact="type 5" post="adenovirus in immunosuppressed syrian hamsters, while ribavirin is largely"/>
 <result pre="oncolytic adenovirus vectorsCancer Res.2006661270127610.1158/0008-5472.CAN-05-349716452178 29.TollefsonA.E.YingB.SpencerJ.F.SagartzJ.E.WoldW.S.TothK.Pathology in permissive syrian hamsters after" exact="infection" post="with human adenovirus is the result of virus replication;"/>
 <result pre="not mice: Comparison of biodistribution studiesCancer Gene Ther.20091662563710.1038/cgt.2009.619197322 31.LichtensteinD.L.SpencerJ.F.DoroninK.PatraD.MeyerJ.ShashkovaE.V.KuppuswamyM.DharD.ThomasM.A.TollefsonA.E.et al.An" exact="acute" post="toxicology study with ingn 007, an oncolytic adenovirus vector,"/>
 <result pre="Each symbol represents the value from an individual animal; the" exact="horizontal" post="bar signifies the mean. Ad6-Vehicle v. Ad6-VGCV p ="/>
 <result pre="Each symbol represents the value from an individual animal; the" exact="horizontal" post="bar signifies the mean. NQ: not quantifiable; ND: not"/>
 <result pre="and decreases Ad6 virus burden in the lungs of immunosuppressed" exact="female" post="Syrian hamsters. (A) Body weight changes. Each symbol represents"/>
 <result pre="Each symbol represents the value from an individual animal; the" exact="horizontal" post="bar signifies the mean. Ad6-Vehicle v. Ad6-VGCV p ="/>
 <result pre="Each symbol represents the value from an individual animal; the" exact="horizontal" post="bar signifies the mean. Statistical significance was not calculated."/>
 <result pre="Each symbol represents the value from an individual animal; the" exact="horizontal" post="bar signifies the mean. Ad6-Vehicle v. Ad6-CDV p ="/>
</results>
